Symbols

EOLS

Evolus·NASDAQ

--(--)

EOLS fundamentals

EOLS Q4 2025 Earnings

Evolus (EOLS) released its earnings on Mar 3, 2026: revenue was 90.30M (YoY +14.38%), beat estimates; EPS was 0.0442 (YoY +35.17%), beat estimates.

Revenue / YoY

90.30M

+14.38%

EPS / YoY

0.0442

+35.17%

Report date

Mar 3, 2026

EOLS Earnings Call Summary for Q4,2025

Revenue Resilience: 12% full-year growth (14% Q4) despite U.S. market decline, driven by Jeuveau (14% share) and Evolysse (3,000+ accounts).
Innovation Momentum: Evolysse Q4 revenue $7.2M; Sculpt FDA approval Q4 2026. Portfolio rebates boost multi-product adoption.
2026 Targets: $327-337M revenue, 13-15% EBITDA margin by 2028, with 0-3% expense growth.
Strategic Moves: Co-branded media campaigns, clinic-specific marketing, and $30M credit facility for Sculpt launch.
Risks & Opportunities: Competing with new toxins; European market showing resilience (UK toxin share 10%).

Earnings

EPS

Revenue

Revenue & Expenses

EOLS has released its 2025 Q4 earnings report, with revenue of 90.30M, reflecting a YoY change of 14.38%, and net profit of 130.00K, showing a YoY change of 101.91%. The Sankey diagram below clearly presents EOLS's revenue sources and cost distribution.

Key Indicators

Evolus (EOLS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Evolus (EOLS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Evolus (EOLS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Evolus (EOLS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown